The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

April 30, 2020

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

April 24, 2020

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

April 23, 2020

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

April 22, 2020

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

April 17, 2020

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

April 16, 2020

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

April 15, 2020

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

April 08, 2020

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

April 03, 2020

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

March 31, 2020

Ajai Chari, MD, discusses the impact of the COVID-19 outbreak on hospital protocols and the measures that are being taken to reduce the spread of the virus.

March 31, 2020

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

March 26, 2020

Joshua Brody, MD, discusses research with in-situ vaccination in non-Hodgkin lymphoma and strategies being developed to overcome acquired resistance.

March 26, 2020

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

March 20, 2020

William K. Oh, MD, discusses sequencing challenges in prostate cancer, biomarker development, and the impact of the PRINT trial.

March 19, 2020

John P. Sfakianos, MD, discusses some of the optimal and evolving management strategies in localized bladder cancer.

March 18, 2020

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

March 13, 2020

Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.

March 12, 2020

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

March 10, 2020

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

March 02, 2020

The International Association for the Study of Lung Cancer (IASLC) announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC CEO, Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology and Associate Director of Biomarker Discovery at The Tisch Cancer Institute at Mount Sinai and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.